MAPK3 and neoplasm: More than activating mutations or amplifications in the ERK1/2 gene, the abnormal activation of these kinases as a consequence of oncogenic mutations in the RAS/RAF/MEK axis promotes cell survival and adaptation to unfavorable conditions, including chemotherapy and immune system anti-tumor response.